For example, YAP-mediated CDK6 overexpression has been reported to be a key driver for the resistance to CDK4/6 inhibitors in BC patients, implying that more potent inhibitors of CDK6 may be valuable as strategies for overcoming drug resistance in clinical trials [58]. This evidence concerns the gene CDK4 and breast cancer.